细胞角蛋白19-2G2和细胞角蛋白19片段抗原在非小细胞肺癌化疗疗效评估中的价值  

Clinical applicability of serum tumor markers （CK-2G2 and Cyfra21-1 ） for efficacy assessment ofchemotherapy in patients with non-small-cell lung cancer

作　　者：吴恩东[1] 宋丽红[1] 勾秀丽 梁子坤[1] 尹颜军 时广利 骆宝建[1] 

机构地区：[1]首都医科大学附属北京胸科医院ICU,101149 [2]检验科

出　　处：《中国医药》2012年第10期1217-1219,共3页China Medicine

摘　　要：目的评价血清肿瘤标志物细胞角蛋白19-2G2（CK-2G2）和细胞角蛋白19片段抗原（Cyfra21-1）在非小细胞肺癌（NSCLC）疗效评估中的临床应用价值。方法应用化学发光法检测124例NSCLC（腺癌74例，鳞癌50例）患者化疗前、化疗1个周期和2个周期血清中CK-2G2和Cyfra21-1的水平。经正态性检验，CK-2G2和Cyfra21-1水平为偏态分布资料，以M（QR）表示，组间和化疗前后比较采用秩和检验。结果腺癌和鳞癌患者化疗1个周期后CK-2G2和Cyfra21-1的水平明显下降[腺癌患者分别为0．77（0．03-55．85）U／L比1．86（0．02-55．60）U／L、1．88（0．15-18．65）μg/L比2．35（0．14-22．32）μg/L；鳞癌患者分别为1．67（0．04-218．60）U／L比4．75（0．05-226．30）U／L、2．12（0．12-20．65）μg/L比4．07（0．11-40．21）μg/L]。疾病进展患者（9例）化疗1个周期后CK-2（32和Cyfra21-1的水平明显升高（P〈0．01）；疾病稳定患者（49例）和部分缓解患者（66例）化疗1个周期后CK-2G2的水平明显下降（P〈0．01）；化疗2个周期后与化疗1个周期后比较，NSCLC患者CK-2G2和Cyfra21-1的水平无明显变化（P〉0．05）。结论肿瘤标志物CK-2G2和Cyfra21-1可作为NSCLC化疗早期疗效评价参考指标。Objective To investigate the clinical significance of cytokeratin 19-2G2 （CK-2G2） and Cyfra21-1 for assessment of efficacy of chemotherapy in patients with non-small-cell lung cancer. Methods The serum levels of CK-2G2 and Cyfra21-1 were detected by Chemiluminescence （CLIA） in 124 patients with non-small- cell lung cancer before chemotherapy, after treatment for one period and after treatment for two periods. Results The levels of CK-2G2 and Cyfra21-1 in patients with adenocarcinoma after treatment for one period were significantly lower than those of patients before chemotherapy[ 0. 77 （ 0. 03-55.85 ） U/L vs 1.86 （ 0.02-55.60 ） U/L, 1.88 （ 0. 15- 18.65） μg/L vs 2. 35 （0. 14-22. 32）μg/L] （P 〈 0. 05）. The levels of CK-2G2 and Cyfra21-1 in patients with squamous-cell carcinoma after treatment for one period were significantly lower than those of patients before chemotherapy[ 1.67 （ 0. 04-218.60 ） U/L vs 4. 75 （ 0. 05-226. 30 ） U/L, 2. 12 （ 0. 12-20. 65 ） μg/L vs 4. 07 （ 0. 11- 40. 21 ） μg/L] （P 〈0. 01 ）. The levels of CK-2G2 and Cyfra21-1 in patients with progressive disease after treatment for one period were significantly higher than those of patients before chemotherapy（P 〈 0. 01 ）. The levels of CK- 2G2 and Cyfra21-1 in patients with stable disease and partial remission after treatment for one period were significantly lower than those of patients before chemotherapy（ P 〈 0. 01 ）. There were no significant changes of the levels of CK-2G2 and Cyfra21-1 in patients after treatment for two periods compared with patients after treatment for one period （P 〉 0. 05 ）. Conclusion The tumor markers CK-2G2 and Cyfra21-1 are valuable to monitor patients with non-small-cell lung cancer.

关 键 词：非小细胞肺癌 肿瘤标志物 疗效 

分 类 号：R734.2[医药卫生—肿瘤]